Dr. Alan H. Bryce, MD, discusses the newest advances and research in prostate cancer treatments that target androgen receptors, such as BET inhibitors and CYP17 inhibitors, as opposed to chemotherapeutic and radiopharmaceutical approaches.Read More
Alan H. Bryce, MD
Dr. Bryce studies cancer genetics and novel therapeutics with a focus on personalized medicine. His clinical practice centers on genitourinary malignancies (prostate, kidney, bladder, and testicular cancers) and melanoma. He is the Medical Director of the Genomic Oncology Clinic at Mayo Clinic Arizona where he utilizes whole genome sequencing of tumors to identify key driver mutations. This approach allows for precise targeting of a patient’s tumor, leading to a greater chance of remission. In addition, Dr. Bryce participates in community outreach to underserved populations and has in interest in health disparities research. He also conducts Phase I clinical trials of new cancer drugs.
Articles by Alan H. Bryce, MD
Alan H. Bryce, MD, argues that the urologic community should expand genetic testing in prostate cancer patients. With expansive, quality data, urologists will be able to better recognize aberrations in patients’ genes. Also, this would be a step closer to gaining FDA approved biomarkers for prostate cancer.Read More
Dr. Alan H. Bryce, MD, argues that there is not yet enough substantive data and research to justify the FDA approving using adjuvant Sunitinib to treat high risk renal cell carcinoma.Read More
Dr. Alan H. Bryce, MD, discusses synthetic lethality regarding BRCA deficient tumors, the role of PARP inhibitors and resistance to them, and the importance of germline testing when treating cancer patients.Read More
Dr. Alan H. Bryce, MD, discusses the use of immunotherapy for metastatic disease treatment, the proven survival benefit of certain immunotherapeutic drugs, and summarizes recent advances in immunotherapy as a whole.Read More